Institutional flow

Institutional Flow — Scan of Jun 13, 2026

Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.

Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
4funds adding
11new positions
$575.5Mheld by those funds

AIThis scan

We compared the Q1 2026 (reportDate 2026-03-31) 13F-HRs against Q4 2025 (reportDate 2025-12-31) across the five-fund watchlist — Berkshire, Bridgewater, Renaissance Technologies, Citadel, Two Sigma. All five funds returned two clean filings. 898 raw CUSIPs showed some net accumulation; after applying the multi-fund consensus filter (net buyers > trimmers, aggregate shares +25% Q/Q or ≥2 new positions, put-option exclusion, single-fund concentration cap) and the retail-attention rails (sub-$1B mcap drops, ETF drops, mega-cap retail-favorite drops, WSB/StockTwits hotlist drops), five stocks cleared cleanly: TECK, MKSI, NTRS, NPO, and VCYT. The single most surprising finding is who is NOT on this list: Berkshire's loudest Q1 moves — a +204% block buy of Alphabet Class A, complete exits from Amazon, UnitedHealth, Mastercard, Visa, Domino's, Pool Corp, and a 95% cut of Constellation Brands — were entirely solo trades. None of Buffett's accumulations overlapped with what the quants and Bridgewater were building. The two camps are pointing different directions this quarter: Berkshire is rotating inside mega-cap, while the quant/macro cohort is moving down-cap into copper, semi-cap equipment, custody banking, industrial sealing, and reimbursed diagnostics. The five names below are where that quant/macro cohort overlapped.

How this scan was run

For each fund we summed sharesHeld and valueUsd across duplicate CUSIP rows within a single filing (13Fs split positions across sub-portfolios). We computed per-fund Q/Q deltas, then aggregated across the five funds — a CUSIP qualified only when net adders + new positions exceeded trimmers AND aggregate share count rose ≥25% Q/Q OR ≥2 funds opened brand-new positions. Put-option holdings were excluded; calls counted. We dropped CUSIPs where >80% of the aggregate increase came from a single fund (unless Berkshire was the buyer — block buys ARE the signal). CUSIP→ticker: 878742204 resolved to TECK (NYSE ADR, more liquid than TECK.B on TSX); G7S00T104 to PNR. ETFs (First Trust Exchange Traded Fund Trust, Fidelity Covington Trust) were dropped. Quality rails removed mega-cap retail favorites that nominally cleared the screen (MMM, PCAR), microcaps below $1B (Forward Industries, M-Tron Inds, Ethos Tech, Agilon Health, Solv Energy), and heavy-retail tickers (AAL, JBLU). Quant managers (Renaissance, Citadel, Two Sigma) are partial signal due to intra-quarter turnover — we required either Bridgewater participation or a 3-of-4 quant consensus for a candidate to survive thesis-writing. Berkshire returned holdings but failed to overlap with any qualifying candidate; we surfaced that asymmetry in the summary rather than padding the list. No funds failed to return data.

#1

TECK

Teck Resources Limited
MaterialsMkt cap $30.4BNext earnings Jul 23, 2026
Price
$64.84
Est. fund entry
$51.75+25.3%
Shares held
3.02M
Position value
$156.5M
Funds that added
FundPrior sharesShares nowChange
Citadel Advisors1.54M2.00M+30.0%
Two Sigma Investments—814.9KNew position
Renaissance Technologies—197.9KNew position
Bridgewater Associates—13.7KNew position
Retail attention 4 of 4 signals quiet
Google Trends22/100quiet
News, 30 days14 articlesquiet
Call/put OI1.30quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Citadel ran a +30% Q/Q add while Bridgewater, Renaissance, and Two Sigma all opened new positions on the same name in the same quarter — a 4-way overlap is rare for an industrial commodity name this far down the cap stack. The trade is copper. Teck closed the steelmaking-coal divestiture to Glencore in 2024 and is now pure-play base metals (copper + zinc + the QB2 ramp in Chile). Bridgewater's macro book has been adding commodity exposure into a back-half setup where Chinese stimulus and US grid/data-center buildout collide with a structurally tight copper market. Q1 (reported April 23) confirmed QB2 is past commissioning. Catalyst retail hasn't priced: a clean second-half QB2 production ramp and the live possibility of a takeout bid from Glencore or an Anglo at any pullback.

What would prove it wrong

Copper is a China call — if property and grid stimulus disappoints, the whole base-metals complex rolls and TECK rolls with it. Zinc strength flattered the Q1 beat and is more cyclical than the copper book.

#2

MKSI

MKS Inc
Information TechnologyMkt cap $24.0BNext earnings Aug 5, 2026
Price
$355.69
Est. fund entry
$229.81+54.8%
Shares held
1.40M
Position value
$321.4M
Funds that added
FundPrior sharesShares nowChange
Citadel Advisors502.7K978.1K+94.6%
Two Sigma Investments29.4K278.7K+849.3%
Renaissance Technologies—103.6KNew position
Bridgewater Associates—38.1KNew position
Retail attention 4 of 4 signals quiet
Google Trends12/100quiet
News, 30 days9 articlesquiet
Call/put OI1.20quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Two Sigma went from a starter stake to 278K shares (+849%), Citadel nearly doubled, and Bridgewater and Renaissance both opened new positions — four-fund agreement on a non-headline semi name. MKS sells the photonic systems, vacuum solutions, and process-control instruments that sit inside every advanced lithography, deposition, etch, and metrology tool — one layer deeper than ASML and Lam in the AI-capex stack, and trading at roughly 14x forward EPS versus 30x+ for the headline names. Q1 EPS of $2.30 came in ~12% above consensus. Catalyst retail hasn't priced: the new $100M Malaysia facility came online in June explicitly built for the $170–180B WFE cycle management is guiding to in 2027, which is a year ahead of sell-side models.

What would prove it wrong

Semi-cap is cyclical and binary on China export-control headlines; any memory-price reset or WFE pause hits MKSI alongside the bigger names. Some Q1 strength was pull-in from advanced packaging customers and may not repeat at the same slope.

#3

NTRS

Northern Trust Corporation
FinancialsMkt cap $33.1BNext earnings Jul 21, 2026
Price
$174.34
Est. fund entry
$139.57+24.9%
Shares held
409.7K
Position value
$57.2M
Funds that added
FundPrior sharesShares nowChange
Citadel Advisors197.8K310.8K+57.1%
Two Sigma Investments—67.8KNew position
Renaissance Technologies—16.5KNew position
Bridgewater Associates10.9K14.7K+34.4%
Retail attention 4 of 4 signals quiet
Google Trends10/100quiet
News, 30 days12 articlesquiet
Call/put OI1.00quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Citadel +57% on an already-large position, Bridgewater added 34% on top, Two Sigma and Renaissance both opened new positions. Custody and trust banks have been treated as a State Street/BNY story while Northern Trust has quietly been the higher-fee-mix, higher-wealth-skew name. Bridgewater's exposure here fits its diversified-financials overweight that began Q3 2025. Catalyst retail hasn't priced: NTRS filed for exemptive relief on June 8 to introduce ETF share classes within its multi-series trusts — if approved (the SEC has been receptive to similar filings), it monetizes a distribution channel that competitors structurally can't match, and management just reorganized asset-servicing leadership on June 1 to capitalize on it.

What would prove it wrong

A faster-than-expected Fed cutting cycle squeezes net interest income and resets the rate-sensitive part of the thesis. The 90-day share return is already ~24%, so some of the recovery is in the tape.

#4

NPO

Enpro Inc.
IndustrialsMkt cap $7.0BNext earnings Aug 5, 2026
Price
$334.60
Est. fund entry
$250.65+33.5%
Shares held
94.9K
Position value
$23.8M
Funds that added
FundPrior sharesShares nowChange
Citadel Advisors4.65K13.4K+188.4%
Renaissance Technologies24.1K50.1K+107.9%
Two Sigma Investments—29.7KNew position
Bridgewater Associates—1.66KNew position
Retail attention 4 of 4 signals quiet
Google Trends8/100quiet
News, 30 days7 articlesquiet
Call/put OI0.90quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Citadel +188%, Renaissance +108%, plus brand-new positions from Two Sigma and Bridgewater — four-way agreement on a name nobody covers. Enpro is two segments most analysts skip: Sealing Technologies for semiconductor wet-process and biopharma single-use, and Advanced Surface Technologies. Q1 raised full-year revenue guidance to 10–14% growth (from 8–12%) and KeyBanc moved the price target to $345. Catalyst retail hasn't priced: the just-closed AlpHa Measurement Solutions and Overlook Industries acquisitions add recurring biopharma analytical-sensing revenue that sell-side models haven't refreshed — the segment mix shift improves margin profile materially before the next print.

What would prove it wrong

Semiconductor exposure cuts both ways — a wafer-fab spending pause drags Enpro down with the rest of the supply chain. Float is small (~21M shares); any miss or M&A-integration stumble amplifies into the print.

#5

VCYT

Veracyte, Inc.
Health CareMkt cap $3.7BNext earnings Aug 5, 2026
Price
$47.33
Est. fund entry
$32.21+46.9%
Shares held
518.6K
Position value
$16.7M
Funds that added
FundPrior sharesShares nowChange
Renaissance Technologies—223.5KNew position
Bridgewater Associates28.4K91.6K+222.6%
Citadel Advisors159.7K184.8K+15.8%
Two Sigma Investments—18.7KNew position
Retail attention 4 of 4 signals quiet
Google Trends18/100quiet
News, 30 days10 articlesquiet
Call/put OI1.10quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Renaissance opened a 223K-share new position, Bridgewater tripled, Two Sigma went new, Citadel topped up — and Bridgewater tripling a small-cap diagnostics name is the unusual signal here, since their healthcare book skews larger. Veracyte sells Decipher (prostate), Afirma (thyroid), and now TrueMRD molecular residual disease assays. Q1 revenue grew 21% and testing revenue 26%. Catalyst retail hasn't priced: CMS issued Molecular Diagnostics Services coverage for TrueMRD in muscle-invasive bladder cancer on May 15, with commercial availability starting June 1 — that's a brand-new reimbursable indication layering on the existing growth algorithm, and the Street hasn't refreshed numbers for what TrueMRD adds in 2027.

What would prove it wrong

MRD competition (Natera, Guardant) is intense and reimbursement pricing can compress the gross-margin runway over the next two years. Any CMS rate cut on existing tests would derate the multiple before the new product layers in.

All scans

Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones — while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartCreate a free account

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.